AbbVie presents strong data on Crohn's and ulcerative colitis treatments risankizumab and upadacitinib at DDW 2026

AbbVie showcased 18 abstracts at the 2026 Digestive Disease Week, highlighting real-world and clinical trial data for its gastroenterology drugs risankizumab (SKYRIZI) and upadacitinib (RINVOQ) in treating Crohn's disease and ulcerative colitis. The data demonstrated sustained symptom relief, improved quality of life, and lower hospitalization rates, reinforcing the drugs' efficacy, safety, and durability. Notably, risankizumab showed low treatment switch rates, and upadacitinib reduced hospitalizations compared to biologic dose escalation. These findings support AbbVie's leadership in advancing inflammatory bowel disease care and may influence future treatment guidelines and approvals.